Cerebrolysin
FPF-1070 / Brain-Derived Peptide Preparation
Cerebrolysin is a porcine brain-derived peptide mixture consisting of low-molecular-weight neuropeptides and free amino acids obtained through standardized enzymatic proteolysis of pig brain proteins. It is approved in over 40 countries for the treatment of stroke, traumatic brain injury, and various forms of dementia, though it has not received FDA approval in the United States. Administration is exclusively via intravenous or intramuscular injection, with treatment protocols typically spanning 10-30 days.
Meccanismo d'azione
Porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids. Exhibits neurotrophic activity mimicking BDNF, GDNF, NGF, and CNTF. Promotes neuronal sprouting, synaptogenesis, and neurogenesis. Reduces neuroinflammation.
Protocolli di ricerca
Solo per scopi di ricerca. Non è consiglio medico.
Clinical protocols use 10-30ml IV infusion daily for 10-20 day cycles. Repeated every 3-6 months. Some protocols use 5-10ml intramuscularly. Not a single peptide — it is a standardized mixture.
Note di ricerca
Clinical Research Status
Cerebrolysin has been studied in numerous randomized controlled trials for acute ischemic stroke, traumatic brain injury, and vascular dementia. The CASTA trial and other large studies have shown mixed results, with some demonstrating improved functional outcomes while others failed to reach primary endpoints. It remains one of the most extensively studied neuropeptide preparations globally despite lacking FDA approval.
Key Published Findings
Research demonstrates neurotrophic activity similar to naturally occurring nerve growth factors, promoting neuronal sprouting, synaptic formation, and neurogenesis. Studies in Alzheimer's disease patients have shown improvements in cognitive function and global clinical assessments over 6-month treatment periods. Animal models consistently demonstrate reduced infarct volume and improved behavioral outcomes following induced stroke.
Safety Profile
The most common adverse effects include headache, dizziness, and injection site reactions, with serious adverse events occurring at rates similar to placebo in controlled trials. Allergic reactions are possible due to the porcine-derived nature of the product, though anaphylaxis is rare. It is contraindicated in patients with epilepsy, severe renal impairment, and known hypersensitivity to porcine proteins.
Comparison to Related Compounds
Unlike single-peptide nootropics such as Semax or Selank, Cerebrolysin is a complex mixture containing multiple bioactive fragments that may act synergistically on various neurotrophic pathways. Cortexin is a similar porcine brain-derived preparation but with distinct manufacturing processes and somewhat different peptide profiles. Compared to synthetic nootropics, Cerebrolysin's multi-target mechanism may offer broader neuroprotection but complicates mechanistic understanding.
Community Observations
Users frequently report improved mental clarity, enhanced recovery from brain injuries, and better cognitive function during treatment cycles. The requirement for IV/IM administration limits self-experimentation, and many users travel to countries where it is available over-the-counter. Cost and accessibility remain significant barriers, with some users sourcing from Eastern European or Asian pharmacies.
Semplifichro
~Minutes (component peptides); neurotrophic effects last hours
Riconcimimento
Pre-mixed injectable solution (no reconstitution)
Conservazione
Lyofilizzato
Room temperature up to 25C. Protect from light.
Riconcimato
Use immediately after opening ampule. Single-use only.
Stato legale USA
Anche noto come
Domande frequenti
Che cos'è Cerebrolysin?
Cerebrolysin is a porcine brain-derived peptide mixture consisting of low-molecular-weight neuropeptides and free amino acids obtained through standardized enzymatic proteolysis of pig brain proteins. It is approved in over 40 countries for the treatment of stroke, traumatic brain injury, and various forms of dementia, though it has not received FDA approval in the United States. Administration is exclusively via intravenous or intramuscular injection, with treatment protocols typically spanning 10-30 days.
Come agisce Cerebrolysin?
Porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids. Exhibits neurotrophic activity mimicking BDNF, GDNF, NGF, and CNTF. Promotes neuronal sprouting, synaptogenesis, and neurogenesis. Reduces neuroinflammation.
Qual è lo stato normativo di Cerebrolysin negli Stati Uniti?
Not FDA-approved (approved in 40+ other countries)
Qual è l'emivita di Cerebrolysin?
~Minutes (component peptides); neurotrophic effects last hours
Con quali altri nomi è noto Cerebrolysin?
FPF-1070, Brain-Derived Peptide Preparation
Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.
Leggi l'intera dichiarazione di responsabilità